Biotechnology

Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies

June 29, 2026 9:36 AM

Edison Scientific and Population Health Partners (PHP) today announced a strategic partnership to create and launch new biotechnology companies focused on some of the world's largest health challenges. Edison Scientific and Population Health Partners announce a strategic partnership. / Source: Edison Scientific (EZ Newswire) Under the partnership, Edison and PHP will combine PHP's track record of building successful biotechnology companies with...

Read more

SilvaBio and Foray Bioscience Announce Collaboration to Accelerate Restoration of the American Chestnut

June 29, 2026 8:30 AM

Today, SilvaBio, the forest biotechnology company that develops, produces, and sells disease-tolerant hardwood seedlings, and Foray Bioscience, a plant biomanufacturing company growing plant products from the cell up, announce a collaboration focused on exploring how producing fabricated seeds can accelerate the restoration of the American chestnut. This partnership will pair SilvaBio's genetics expertise, accelerated breeding, and restoration...

Read more

FluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer Trial

June 29, 2026 4:50 AM

FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer. Key data: 19 patients screened, 15 patients enrolled and completed surgery, completing the first part of the trial and allowing...

Read more

OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares

June 25, 2026 8:32 AM

OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026. One CVR for every share owned. The Board of Directors has authorized management to proceed with implementation, subject to receipt of a...

Read more

DiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of Directors

June 25, 2026 7:00 AM

DiscGenics, Inc., a privately held, late-stage clinical biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the appointment of Chad Falciani to its Board of Directors. Mr. Falciani is a proven healthcare entrepreneur, investor, and business leader and is the Founder and Chairman of Curiteva, a high-growth medical...

Read more

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

June 24, 2026 4:10 PM

eXoZymes Inc. (NASDAQ:EXOZ) - a pioneer of AI-enhanced enzymes that enable scalable manufacturing of nutraceuticals and novel pharmaceuticals - today announced that it has received a Notice of Award from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518. The NIH funded work is expected to begin July 1, 2026, and...

Read more

Thalia Therapeutics PLC Announces Acquisition and £2.75 Million Fundraise

June 24, 2026 2:15 AM

Thalia Therapeutics plc (AIM:THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease is pleased to announce the acquisition, conditional upon shareholder approval, of Sanmirna Therapeutics, Inc. ("Sanmirna"), a US Corporation which holds an exclusive licence for the intellectual property and know-how around miRisten an anti-microRNA-126 for the treatment of...

Read more

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

June 23, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease and AI-enabled healthcare technologies, today announced the beta version of its proprietary Agentic Harmonization Assistant ("AHA"), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. The announcement comes as IGC...

Read more

Deeply Cultivating Brain Disease Sector, Cloud-Clone Wuhan Forges New Edges in CRO Services

June 22, 2026 10:00 AM

World Parkinson's Day, observed on April 11 annually, continuously raises public awareness of the health and public health burdens brought by Parkinson's disease and other brain disorders. At present, brain diseases such as neurodegenerative illnesses, stroke and traumatic brain injury have emerged as critical global public health challenges. Constrained by complicated pathogenic mechanisms, numerous drug targets and the special physiological...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

June 22, 2026 9:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Faron Pharmaceuticals Ltd | Company announcement | June 22, 2026 at 16:00:00 EEST Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer: FARON PHARMACEUTICALS OY 2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An...

Read more

OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do

June 22, 2026 9:06 AM

OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly reflects the Company's mission. The change became effective on June 11, 2026 upon the filing of a Certificate of Amendment with the Delaware Secretary of State. The rebrand is a clearer articulation of the Company's identity as a global health innovation platform operating across...

Read more

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

June 22, 2026 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company setting new standards of care for the treatment of deep venous disease, today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. As part of the discussion, the Company's CEO, Rob Berman, will provide an overview of enVVeno Medical's mission to transform the treatment of deep venous disease,...

Read more

Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement

June 17, 2026 9:05 PM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and...

Read more

Cenna Biosciences Receives FDA Clearance to Begin Phase 1a/1b Clinical Trial of 8M2D, a First-in-Class Peptide Designed to Stop the Production of Amyloid in Alzheimer's Disease

June 17, 2026 6:25 PM

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of Cenna Biosciences (Cenna) to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide for the treatment of Alzheimer's disease (AD). 8M2D is designed to address the root cause of AD by inhibiting the production of β-amyloid (Aβ), rather than clearing it after it has already accumulated in the brain. "FDA clearance of our IND is a...

Read more

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

June 17, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company")is pleased to announce the successful final completion of its comparative mouse study (the "Study") evaluating protamine-enhanced skin permeation delivery of GLP/GIP-based therapies1. The Study has now been completed for both semaglutide and tirzepatide, with closely aligned and reproducible results observed across the two molecules. As...

Read more

eXoZymes Inc. Announces Closing of $6 Million Public Offering

June 17, 2026 4:10 PM

eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants. The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

June 17, 2026 9:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 16:30:00 EEST TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd 1b. Please...

Read more

Commonwealth of Massachusetts Honors Longwood Fund and Christoph Westphal with Governor's Citation

June 17, 2026 7:00 AM

Longwood Fund, a venture capital firm creating and investing in science-based companies that develop important treatments to help patients, today announced that Massachusetts Governor Maura Healey honored Longwood Fund and Christoph Westphal, MD, PhD, General Partner of Longwood Fund, with the presentation of the Governor's Citation, recognizing Dr. Westphal's career as a physician-scientist, entrepreneur, investor, and CEO, advancing...

Read more

Year-End Report 2025-2026

June 17, 2026 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Strong growth provides the platform for the next commercial phase Biovica ended the fiscal year with strong growth in both the fourth quarter and for the full fiscal year, while making important progress in expanding the clinical evidence base, the Pharma Services area, and adoption of DiviTum TKa in the USA. Biovica is embarking on the next commercial phase with a sharper focus,...

Read more

Faron Pharmaceuticals LTD: Holding(S) In Company

June 17, 2026 2:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer: FARON PHARMACEUTICALS OY 2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An...

Read more